New Horizon Medical

New Horizon Health is a leading Chinese biotechnology company specializing in the early detection and screening of high-incidence cancers. The company's flagship product, ColoClear, is the first and only molecular cancer screening test approved by China's National Medical Products Administration (NMPA). New Horizon Health focuses on non-invasive home-based screening solutions, utilizing advanced molecular biology and proprietary algorithms to identify cancer-related biomarkers. Their portfolio includes commercialized tests for colorectal and gastric cancers, with a robust pipeline targeting cervical, liver, and nasopharyngeal cancers. The company is headquartered in Hangzhou and is listed on the Hong Kong Stock Exchange.